Avanos Medical (AVNS)
Market Price (4/16/2026): $24.65 | Market Cap: $1.1 BilSector: Health Care | Industry: Health Care Supplies
Avanos Medical (AVNS)
Market Price (4/16/2026): $24.65Market Cap: $1.1 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. | Trading close to highsDist 52W High is 0.0% Weak multi-year price returns2Y Excs Rtn is -7.9%, 3Y Excs Rtn is -90% | Stock price has recently run up significantly6M Rtn6 month market price return is 118%, 12M Rtn12 month market price return is 105% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.9% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 113% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10% Key risksAVNS key risks include [1] persistent and widening losses driven by a lack of revenue and earnings growth, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. |
| Trading close to highsDist 52W High is 0.0% |
| Weak multi-year price returns2Y Excs Rtn is -7.9%, 3Y Excs Rtn is -90% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 118%, 12M Rtn12 month market price return is 105% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.9% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 113% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10% |
| Key risksAVNS key risks include [1] persistent and widening losses driven by a lack of revenue and earnings growth, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Avanos Medical (AVNS) stock has gained about 120% since 12/31/2025 because of the following key factors:
1. Acquisition by American Industrial Partners (AIP) at a Significant Premium.
Avanos Medical (AVNS) announced on April 14, 2026, that it had entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.27 billion. This deal offers Avanos stockholders $25.00 per share in cash, representing a substantial 72.1% premium over the closing price on April 13, 2026, and an 82.8% premium to the 30-day volume-weighted average share price as of the same date. The announcement alone caused Avanos shares to surge by over 69% in early trading. This acquisition is the primary driver of the significant stock movement since December 31, 2025.
2. Strong Fourth Quarter 2025 Earnings Beat and Positive 2026 Guidance.
Prior to the acquisition announcement, Avanos Medical reported robust financial results for the fourth quarter of 2025 on February 24, 2026, exceeding analyst expectations. The company posted an adjusted earnings per share (EPS) of $0.29, surpassing the consensus estimate of $0.25 by $0.04. Additionally, revenue for the quarter reached $180.9 million, exceeding the $169 million estimate and marking a 0.7% increase year-over-year. The Specialty Nutrition Systems segment notably grew by 8.7% year-over-year to $115.1 million. Avanos also provided optimistic guidance for fiscal year 2026, forecasting mid-single-digit revenue growth. This positive earnings report and outlook contributed to strong investor confidence and upward momentum in the stock.
Show more
1. Acquisition by American Industrial Partners (AIP) at a Significant Premium.
Avanos Medical (AVNS) announced on April 14, 2026, that it had entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.27 billion. This deal offers Avanos stockholders $25.00 per share in cash, representing a substantial 72.1% premium over the closing price on April 13, 2026, and an 82.8% premium to the 30-day volume-weighted average share price as of the same date. The announcement alone caused Avanos shares to surge by over 69% in early trading. This acquisition is the primary driver of the significant stock movement since December 31, 2025.
2. Strong Fourth Quarter 2025 Earnings Beat and Positive 2026 Guidance.
Prior to the acquisition announcement, Avanos Medical reported robust financial results for the fourth quarter of 2025 on February 24, 2026, exceeding analyst expectations. The company posted an adjusted earnings per share (EPS) of $0.29, surpassing the consensus estimate of $0.25 by $0.04. Additionally, revenue for the quarter reached $180.9 million, exceeding the $169 million estimate and marking a 0.7% increase year-over-year. The Specialty Nutrition Systems segment notably grew by 8.7% year-over-year to $115.1 million. Avanos also provided optimistic guidance for fiscal year 2026, forecasting mid-single-digit revenue growth. This positive earnings report and outlook contributed to strong investor confidence and upward momentum in the stock.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 120.1% change in AVNS stock from 12/31/2025 to 4/15/2026 was primarily driven by a 119.2% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4152026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.23 | 24.72 | 120.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 700 | 701 | 0.2% |
| P/S Multiple | 0.7 | 1.6 | 119.2% |
| Shares Outstanding (Mil) | 46 | 46 | 0.2% |
| Cumulative Contribution | 120.1% |
Market Drivers
12/31/2025 to 4/15/2026| Return | Correlation | |
|---|---|---|
| AVNS | 120.1% | |
| Market (SPY) | -5.4% | 27.1% |
| Sector (XLV) | -4.5% | 17.5% |
Fundamental Drivers
The 113.8% change in AVNS stock from 9/30/2025 to 4/15/2026 was primarily driven by a 111.2% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4152026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.56 | 24.72 | 113.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 692 | 701 | 1.3% |
| P/S Multiple | 0.8 | 1.6 | 111.2% |
| Shares Outstanding (Mil) | 46 | 46 | 0.0% |
| Cumulative Contribution | 113.8% |
Market Drivers
9/30/2025 to 4/15/2026| Return | Correlation | |
|---|---|---|
| AVNS | 113.8% | |
| Market (SPY) | -2.9% | 28.3% |
| Sector (XLV) | 6.6% | 17.3% |
Fundamental Drivers
The 72.5% change in AVNS stock from 3/31/2025 to 4/15/2026 was primarily driven by a 70.3% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4152026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.33 | 24.72 | 72.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 688 | 701 | 1.9% |
| P/S Multiple | 1.0 | 1.6 | 70.3% |
| Shares Outstanding (Mil) | 46 | 46 | -0.6% |
| Cumulative Contribution | 72.5% |
Market Drivers
3/31/2025 to 4/15/2026| Return | Correlation | |
|---|---|---|
| AVNS | 72.5% | |
| Market (SPY) | 16.3% | 40.4% |
| Sector (XLV) | 2.6% | 24.3% |
Fundamental Drivers
The -16.9% change in AVNS stock from 3/31/2023 to 4/15/2026 was primarily driven by a -14.4% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4152026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.74 | 24.72 | -16.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 722 | 701 | -2.9% |
| P/S Multiple | 1.9 | 1.6 | -14.4% |
| Shares Outstanding (Mil) | 46 | 46 | 0.0% |
| Cumulative Contribution | -16.9% |
Market Drivers
3/31/2023 to 4/15/2026| Return | Correlation | |
|---|---|---|
| AVNS | -16.9% | |
| Market (SPY) | 63.3% | 34.0% |
| Sector (XLV) | 19.5% | 26.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AVNS Return | -24% | -22% | -17% | -29% | -29% | 119% | -46% |
| Peers Return | 10% | 2% | 19% | 20% | 24% | -11% | 76% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 85% |
Monthly Win Rates [3] | |||||||
| AVNS Win Rate | 33% | 42% | 42% | 50% | 33% | 75% | |
| Peers Win Rate | 50% | 52% | 55% | 60% | 60% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| AVNS Max Drawdown | -36% | -43% | -35% | -31% | -38% | -0% | |
| Peers Max Drawdown | -8% | -21% | -7% | -4% | -1% | -15% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABT, CAH, SYK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/15/2026 (YTD)
How Low Can It Go
| Event | AVNS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -67.0% | -25.4% |
| % Gain to Breakeven | 202.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -40.0% | -33.9% |
| % Gain to Breakeven | 66.7% | 51.3% |
| Time to Breakeven | 197 days | 148 days |
| 2018 Correction | ||
| % Loss | -56.1% | -19.8% |
| % Gain to Breakeven | 127.8% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -50.6% | -56.8% |
| % Gain to Breakeven | 102.5% | 131.3% |
| Time to Breakeven | 766 days | 1,480 days |
Compare to MDT, BSX, ABT, CAH, SYK
In The Past
Avanos Medical's stock fell -67.0% during the 2022 Inflation Shock from a high on 2/17/2021. A -67.0% loss requires a 202.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Avanos Medical (AVNS)
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
AI Analysis | Feedback
- Avanos Medical is like the **Medtronic** of specialized chronic care and non-opioid pain management devices for hospitals.
- It's like **BD (Becton, Dickinson and Company)**, but exclusively focused on manufacturing devices for patient feeding, respiratory support, and non-opioid pain relief in healthcare settings.
AI Analysis | Feedback
- Mic-Key enteral feeding tubes: Tubes designed for delivering nutrition and medication directly into the gastrointestinal tract.
- Corpak patient feeding solutions: Comprehensive solutions and devices for patient enteral feeding.
- NeoMed neonatal and pediatric feeding solutions: Specialized feeding solutions tailored for the unique needs of neonates and pediatric patients.
- Respiratory health products (e.g., Ballard, Microcuff, Endoclear): A range of devices including closed airway suction systems and other airway management tools.
- On-Q and ambIT surgical pain pumps: Non-opioid pain pumps used to deliver targeted pain relief post-surgery.
- Game Ready cold and compression therapy systems: Systems that combine active compression and cold therapy for injury recovery and post-operative rehabilitation.
- Coolief pain relief therapy: A minimally invasive, radiofrequency-based procedure for managing chronic pain.
AI Analysis | Feedback
```htmlAvanos Medical (AVNS) primarily sells its medical device solutions to other companies and organizations, rather than directly to individuals. Its major customers fall into the following categories:
- Hospitals and other healthcare providers: Avanos Medical markets its products directly to these institutions.
- Healthcare facilities: This includes various types of healthcare facilities that purchase Avanos Medical's products directly.
- Third-party wholesale distributors: These distributors then sell Avanos Medical's products to the end-user healthcare providers and facilities.
AI Analysis | Feedback
nullAI Analysis | Feedback
David Pacitti, Chief Executive Officer
Mr. Pacitti was appointed Chief Executive Officer of Avanos Medical, Inc. on April 14, 2025. Prior to joining Avanos, he served as President of Siemens Medical Solutions USA, Inc. and Head of the Americas for Siemens Healthineers since 2015, where he was responsible for leading marketing, sales, service, and support functions across North and Latin America for their entire portfolio. Before Siemens Healthineers, he held several leadership positions at Abbott Vascular, including Division VP of U.S. Commercial Operations, Sales & Marketing, overseeing their North American business and playing a key role in launching their first drug-eluting stent and structural heart franchises. He joined Abbott Vascular through its acquisition of Guidant, where he held roles of increasing responsibility from 1995 to 2006.
Scott Galovan, Senior Vice President and Chief Financial Officer
Mr. Galovan was appointed Senior Vice President and Chief Financial Officer of Avanos Medical, effective August 1, 2025. He joined Avanos in 2013 during its spinoff from Kimberly-Clark and most recently served as the company's Senior Vice President of Strategy and Corporate Development. At Avanos, he has a proven track record of leading numerous acquisition and divestiture initiatives, including the sale of the Surgical & Infection Prevention business to Owens & Minor, the Respiratory Health business to AirLife (formerly SunMed), and the acquisitions of CORPAK, Game Ready, Summit Medical, NeoMed, OrthogenRx, and Diros Medical. Before joining Avanos, he spent 10 years in various strategy, finance, and M&A roles at Newell Brands, Equity Pacific Partners (where he was a Principal), and Intel Capital (where he was an Investment Director).
Camille Chang Gilmore, Senior Vice President and Chief Human Resources Officer
Ms. Chang Gilmore is responsible for Avanos Medical’s global people strategy, which encompasses talent acquisition, workforce planning, leadership development, and the overall employee experience. Her leadership focuses on fostering a workplace culture where employees feel valued, empowered, and inspired.
Sigfrido Delgado, Senior Vice President, Operations
Mr. Delgado serves as the Senior Vice President of Operations for Avanos Medical.
Kerr W. Holbrook, Senior Vice President and Chief Commercial Officer
Mr. Holbrook is the Senior Vice President and Chief Commercial Officer at Avanos Medical.
AI Analysis | Feedback
Here are the key risks to Avanos Medical (AVNS):
- Regulatory Changes and Reimbursement Pressures: Avanos Medical faces significant risk from changes in governmental regulations and reimbursement policies, particularly concerning its pain management solutions. This includes pressures on radiofrequency ablation (RFA) products and pending Medicare coverage decisions, which can directly impact product demand and profitability.
- Profitability Challenges and Financial Health: The company has experienced ongoing challenges with profitability, marked by negative net margins and earnings per share. Avanos Medical has also disclosed significant goodwill impairments in recent years (e.g., $77.0 million in 2025 and $336.5 million in 2024), indicating that prior expectations in its Pain Management & Recovery segment were overly optimistic. Additionally, an Altman Z-Score suggesting financial distress implies a potential risk of bankruptcy within the next two years.
- Tariffs, Supply Chain Disruptions, and Manufacturing Concentration: Avanos Medical is exposed to significant and increasing tariff impacts, with an estimated $30 million impact projected for 2026, primarily from China-sourced products. While the company is actively mitigating this by exiting China manufacturing, ongoing disruptions in the supply of raw materials or the distribution of finished goods, alongside a concentration of manufacturing operations in Mexico, pose material operational and financial risks.
AI Analysis | Feedback
null
AI Analysis | Feedback
Avanos Medical (symbol: AVNS) operates in several medical technology markets, including chronic care and non-opioid pain solutions. The addressable markets for its main products and services are sized as follows:
Chronic Care Products
Digestive Health (Enteral Feeding Devices)
- The global enteral feeding devices market was valued at approximately USD 6.5 billion in 2024 and is projected to reach USD 11.6 billion by 2034. Other estimates for the global market in 2024 range from USD 3.89 billion to USD 4.5 billion.
- The U.S. enteral feeding devices market was valued at USD 1.9 billion in 2024. North America is projected to dominate the global enteral feeding devices market in 2024, accounting for approximately 43% of the total share.
Respiratory Health (Respiratory Care Devices)
- The global respiratory care devices market size was valued at USD 23.82 billion in 2024 and is expected to reach USD 47.47 billion by 2032. Another estimate places the global market at USD 23.5 billion in 2024, reaching USD 43.5 billion by 2033.
- North America dominates the global respiratory care devices market, holding approximately 58.5% of the market share, with the U.S. accounting for about 45% of the global market share in 2024.
Non-Opioid Pain Solutions
Acute Pain and Interventional Pain (Non-Opioid Pain Management and Radiofrequency Ablation)
- The global non-opioid pain treatment market size was estimated at USD 48.38 billion in 2024 and is expected to reach around USD 96.25 billion by 2034. Other estimates for the global market in 2024 range from USD 45,321.9 million to USD 53.07 billion.
- The U.S. non-opioid pain treatment market size was valued at USD 17.08 billion in 2024. North America dominated the global non-opioid pain treatment market with a revenue share of 50% in 2024.
- Specifically for interventional pain solutions like Coolief, the global radiofrequency ablation devices market size was valued at USD 4.63 billion in 2024 and is expected to reach nearly USD 11.31 billion by 2032. Another report estimated the global market size at USD 5.07 billion in 2024, projected to grow to USD 14.23 billion by 2033.
- North America holds the highest share in the global radiofrequency ablation devices market in 2024.
AI Analysis | Feedback
Avanos Medical (AVNS) anticipates several key drivers to fuel its revenue growth over the next two to three years:- Strong Organic Growth in Specialty Nutrition Systems (SNS): The SNS segment is expected to continue its robust performance, building on the double-digit organic growth observed in its short-term enteral feeding portfolio and high single-digit growth in long-term feeding. This includes sustained demand for products like Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
- Impact from Recently Launched Products and Portfolio Expansion: The successful and better-than-anticipated adoption of the CORGRIP tube retention system, launched in late 2024, is contributing significant momentum. Additionally, the ongoing U.S. expansion of the CORTRAK standard-of-care offering and the "Go Direct" transition in the U.K. for enteral feeding are expected to further drive revenue.
- Strategic Acquisitions: The acquisition and successful integration of Nexus Medical into the neonatal portfolio is expected to be a double-digit organic growth contributor in 2026. Avanos Medical's long-term strategy also includes pursuing synergistic merger and acquisition opportunities to achieve its target of $1 billion in revenue by 2030.
- Growth in Interventional Pain Solutions (Radiofrequency Ablation - RFA): The company's interventional pain solutions, particularly the radiofrequency ablation (RFA) business, has consistently demonstrated double-digit organic growth within the Pain Management & Recovery segment and is expected to continue this positive trend.
- Strategic Pricing Initiatives: Avanos plans to implement strategic pricing actions, which are expected to contribute to earnings per share (EPS) expansion in 2026, thereby directly impacting revenue growth.
AI Analysis | Feedback
Share Repurchases
- Avanos Medical announced a share repurchase program authorizing the company to purchase up to $30 million of its common stock in December 2021.
- The company repurchased $25 million of its common stock under a share repurchase program in 2025.
- Avanos approved a new one-year program in November 2024 to repurchase up to $25 million of its common stock.
Share Issuance
- Information regarding significant dollar amounts of shares issued by Avanos Medical was not explicitly available within the provided search results for the specified period.
Outbound Investments
- Avanos acquired OrthogenRx, Inc. on January 20, 2022, to enhance its interventional pain portfolio.
- In 2023, Avanos completed the acquisition of Diros Technology Inc. for $53.0 million, adding innovative radiofrequency ablation (RFA) products.
- Avanos acquired Nexus Medical, LLC in 2025 for $27.0 million plus up to $20.0 million in contingent consideration, expanding its vascular access market portfolio.
- The company divested its Respiratory Health business for $110.0 million in 2023 and sold its HA product line and Game Ready rental business in 2025 as part of its transformation initiatives.
Capital Expenditures
- Avanos Medical's capital expenditures for the first six months of 2025 were $17.7 million.
- Expected capital expenditures for 2026 are approximately $25 million, which is about $7 million lower than 2025.
- The 2026 capital expenditures will primarily support the accelerated exit plan from China for neonatal syringe production, shifting manufacturing to Tijuana, Mexico, and Southeast Asia.
Latest Trefis Analyses
Trade Ideas
Select ideas related to AVNS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 94.33 |
| Mkt Cap | 103.8 |
| Rev LTM | 30,300 |
| Op Inc LTM | 4,515 |
| FCF LTM | 4,846 |
| FCF 3Y Avg | 3,221 |
| CFO LTM | 5,572 |
| CFO 3Y Avg | 3,912 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.5% |
| Rev Chg 3Y Avg | 6.6% |
| Rev Chg Q | 10.1% |
| QoQ Delta Rev Chg LTM | 2.6% |
| Op Mgn LTM | 18.4% |
| Op Mgn 3Y Avg | 17.5% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 20.3% |
| CFO/Rev 3Y Avg | 19.5% |
| FCF/Rev LTM | 16.0% |
| FCF/Rev 3Y Avg | 14.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 103.8 |
| P/S | 3.6 |
| P/EBIT | 19.5 |
| P/E | 28.6 |
| P/CFO | 16.9 |
| Total Yield | 3.9% |
| Dividend Yield | 1.0% |
| FCF Yield 3Y Avg | 3.9% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.3% |
| 3M Rtn | -7.9% |
| 6M Rtn | -7.2% |
| 12M Rtn | 4.2% |
| 3Y Rtn | 19.7% |
| 1M Excs Rtn | -7.1% |
| 3M Excs Rtn | -7.2% |
| 6M Excs Rtn | -12.3% |
| 12M Excs Rtn | -27.6% |
| 3Y Excs Rtn | -50.1% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Specialty Nutrition Systems (SNS) | 396 | ||||
| Pain Management and Recovery (PM&R) | 234 | ||||
| Corporate and Other | 57 | ||||
| Digestive Health | 372 | 340 | 322 | 294 | |
| Interventional pain | 162 | 184 | 102 | 86 | |
| Surgical pain and recovery | 139 | 160 | 163 | 157 | |
| Respiratory health | 158 | 177 | |||
| Total | 688 | 673 | 684 | 745 | 715 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Specialty Nutrition Systems (SNS) | 81 | ||||
| Pain Management and Recovery (PM&R) | 3 | ||||
| Corporate and Other | -480 | ||||
| Total | -396 |
Price Behavior
Price Behavior
| Market Price | $24.72 | |
| Market Cap ($ Bil) | 1.1 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $14.46 | $12.39 |
| DMA Trend | up | up |
| Distance from DMA | 71.0% | 99.6% |
| 3M | 1YR | |
| Volatility | 144.5% | 79.7% |
| Downside Capture | -1.52 | -0.09 |
| Upside Capture | 98.11 | 77.22 |
| Correlation (SPY) | 8.2% | 15.6% |
AVNS Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.70 | 0.84 | 0.90 | 0.84 | 0.86 | 0.87 |
| Up Beta | 2.42 | 2.70 | 2.66 | 2.29 | 0.83 | 0.81 |
| Down Beta | 1.66 | 2.25 | 1.36 | 1.24 | 0.88 | 0.62 |
| Up Capture | 5% | 27% | 96% | 54% | 72% | 54% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 11 | 24 | 35 | 63 | 123 | 361 |
| Down Capture | 20% | -27% | -27% | 10% | 98% | 106% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 10 | 17 | 26 | 60 | 122 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVNS | |
|---|---|---|---|---|
| AVNS | 108.1% | 79.5% | 1.18 | - |
| Sector ETF (XLV) | 9.5% | 16.0% | 0.38 | 21.0% |
| Equity (SPY) | 22.0% | 12.9% | 1.36 | 32.7% |
| Gold (GLD) | 49.0% | 27.5% | 1.44 | 7.6% |
| Commodities (DBC) | 25.0% | 16.1% | 1.38 | 0.2% |
| Real Estate (VNQ) | 17.3% | 13.7% | 0.92 | 22.9% |
| Bitcoin (BTCUSD) | -10.4% | 42.6% | -0.14 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVNS | |
|---|---|---|---|---|
| AVNS | -9.5% | 48.2% | -0.07 | - |
| Sector ETF (XLV) | 6.5% | 14.6% | 0.26 | 31.8% |
| Equity (SPY) | 10.9% | 17.0% | 0.50 | 40.8% |
| Gold (GLD) | 21.9% | 17.8% | 1.01 | 9.0% |
| Commodities (DBC) | 11.5% | 18.8% | 0.50 | 8.4% |
| Real Estate (VNQ) | 4.0% | 18.8% | 0.12 | 34.6% |
| Bitcoin (BTCUSD) | 5.1% | 56.5% | 0.31 | 11.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVNS | |
|---|---|---|---|---|
| AVNS | -1.0% | 45.0% | 0.13 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.47 | 41.9% |
| Equity (SPY) | 13.8% | 17.9% | 0.67 | 48.1% |
| Gold (GLD) | 14.3% | 15.9% | 0.75 | 5.5% |
| Commodities (DBC) | 8.7% | 17.6% | 0.41 | 16.8% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 39.8% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/24/2026 | -10.4% | -8.2% | -10.4% |
| 11/5/2025 | -5.7% | 3.2% | -0.4% |
| 8/5/2025 | -12.1% | -6.5% | 9.8% |
| 2/26/2025 | 0.4% | -3.5% | -9.0% |
| 10/30/2024 | -17.9% | -12.6% | -15.4% |
| 7/31/2024 | 4.2% | -0.1% | 5.0% |
| 5/2/2024 | 4.9% | 4.1% | 6.0% |
| 2/20/2024 | 1.6% | 0.4% | 1.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 10 | 9 |
| # Negative | 10 | 13 | 14 |
| Median Positive | 4.2% | 5.4% | 9.6% |
| Median Negative | -8.1% | -9.6% | -9.7% |
| Max Positive | 13.2% | 18.4% | 20.9% |
| Max Negative | -17.9% | -20.5% | -15.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/24/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 700.00 Mil | 710.00 Mil | 720.00 Mil | 2.2% | Higher New | Guidance: 695.00 Mil for 2025 | |
| 2026 Adjusted Diluted EPS | 0.9 | 1 | 1.1 | 11.1% | Higher New | Guidance: 0.9 for 2025 | |
Prior: Q3 2025 Earnings Reported 11/5/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 690.00 Mil | 695.00 Mil | 700.00 Mil | 3.0% | Raised | Guidance: 675.00 Mil for 2025 | |
| 2025 Adjusted Diluted EPS | 0.85 | 0.9 | 0.95 | 5.9% | Raised | Guidance: 0.85 for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Holbrook, Kerr | SVP, Chief Commercial Officer | Direct | Sell | 11192025 | 11.00 | 15,000 | 165,014 | 922,539 | Form |
| 2 | Blackford, Gary | Direct | Buy | 8152025 | 10.97 | 20,000 | 219,500 | 1,005,233 | Form | |
| 3 | Blackford, Gary | Shares held in trust. | Buy | 8152025 | 10.99 | 40,000 | 439,800 | 439,800 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.